Morgan Stanley analyst Dara Mohsenian lowered the firm’s price target on Clorox (CLX) to $150 from $165 and keeps an Equal Weight rating on the shares. Following a fiscal Q3 EPS miss and lower underlying fiscal year EPS guidance on an underlying basis excluding ERP timing, the firm remains Equal Weight, citing “subdued” underlying organic sales growth and low visibility.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox price target lowered to $145 from $150 at BofA
- Clorox price target lowered to $144 from $151 at JPMorgan
- Clorox’s Financial Outlook: Hold Rating Amid Sales Guidance Revision and Market Challenges
- Clorox price target lowered to $142 from $145 at Wells Fargo
- Clorox Reports Q3 2025 Results Amid Sales Decline